---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-010030"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:39:00.552344+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monopar Q4 net loss $5.2M, cash $140.4M; ALXN1840 NDA planned mid-2026

## Summary
- Q4 2025 net loss $5.2M ($0.61/sh) vs $10.9M ($2.23) YoY; full-year net loss $13.7M ($1.85/sh) vs $15.6M.
- Cash, equivalents and short-term investments $140.4M at Dec 31, 2025, expected to fund operations through Dec 31, 2027.
- NDA submission for ALXN1840 (Wilson disease) planned mid-2026; abstracts accepted at EASL 2026 and AAN 2026.
- Completed underwritten public offering generating ~$91.9M after concurrent stock repurchase in 2025.
- Appointed Susan Rodriguez as Chief Commercial and Strategy Officer for potential ALXN1840 launch.

## SEC filing metadata
- accession: 0001437749-26-010030
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/0001437749-26-010030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/mnpr20260326_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-010030
- JSON: https://secwatch.observer/filing/0001437749-26-010030.json
- Plain text: https://secwatch.observer/filing/0001437749-26-010030.txt

## Key facts
- Earnings Releases
  Monopar Therapeutics reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share.
  - Period: year ended December 31, 2025
  - Net income: Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/0001437749-26-010030-index.htm
- Earnings Releases
  Monopar Therapeutics reported fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share.
  - Period: fourth quarter and full year ended December 31, 2025
  - Net income: Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share
  - Result: reported results
  source text: the fourth quarter and full-year 2025 financial results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/0001437749-26-010030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.